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Objective. This study describes the predictive value of oral epithelial dysplasia (OED) grading as an indicator for malignant
transformation and progression.
Study Design. The records of an Australian-based pathology laboratory were searched for oral mucosal biopsies with
a dysplastic or malignant diagnosis. Examination for an association with progression and malignant transformation without
reinterpretation was performed. Analysis was undertaken using hazard ratios and the Fisher exact test.
Results. A total of 368 patients with a diagnosis of OED were included. Twenty-six patients (7.1%) underwent progression or
malignant transformation; the annual malignant transformation rate was 1%. No other characteristics were associated with
a heightened risk of progression or transformation.
Conclusions. The severity of OED was not associated with risk of malignant transformation, suggesting that the current OED
grading system is not useful for predicting patient outcomes or for determining management strategies. Definitive treatment of
all OED is recommended, until a more reliable progression/transformation system is developed. (Oral Surg Oral Med Oral
Pathol Oral Radiol 2014;117:343-352)Head and neck squamous cell carcinomas are amongst
the most aggressive of tumors, with oral squamous cell
carcinoma (OSCC) representing the vast majority.1 The
tendency for local and regional metastases owing to the
close proximity and uninhibited inﬁltration of local
lymph nodes is high, and this is thought to be the greatest
contributor to the morbidity and mortality associated
with OSCC. Five-year survival rates are reportedly as
low as 9% for some parts of the oral cavity, largely due to
late-stage diagnosis when tumor metastasis has occurred
(TNM stage IV).2 Survival signiﬁcantly increases to
between 66% and 85% when OSCC is detected and
treated before lymph node inﬁltration.2,3 Early detection
also improves morbidity accompanying the treatment of
OSCC, with late-stage diagnosis associated with poorer
quality of life outcomes.4 Although it has not been
previously reported, it follows that diagnosis and
management at the “precancerous” stage would further
improve survival rates.5
OSCC is commonly preceded by a range of tissue and
cellular alterations consistent with carcinoma, yet
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Open access under CC BY-NC-ND license.epithelial dysplasia (OED). These changes often mani-
fest in a clinical mucosal lesion.1,6 Various attempts
have been made to uniformly diagnose and discretely
categorize the continuous scale of tissue changes that is
OED. Many of these systems are based on the classiﬁ-
cation of precursor lesions of other epithelial sites,
including squamous intraepithelial neoplasia of the
cervix and the Ljubljana classiﬁcation of the larynx.7
These classiﬁcations are limited in their suitability for
the oral cavity, which presents a unique local environ-
ment that affects the development and progression of
precursor lesions differently. Smith and Pindborg8
described the ﬁrst system of dysplasia classiﬁcation for
the oral mucosa, which was later adapted by Katz et al.9
The system grades mucosa as presenting with none,
slight, and marked dysplasia; however, it has been crit-
icized by some authors for its complexity.7 The most
recently accepted classiﬁcation developed by the World
Health Organization divides OED into mild, moderate,
and severe dysplasia and carcinoma in situ.1 A 2-tier
system has been developed more recently by Kujan
et al.,10 which categorizes OED into low and high risk of
undergoing malignant transformation, in an attempt toStatement of Clinical Relevance
This study conﬁrms that the current system of oral
epithelial dysplasia grading is not useful for pre-
dicting patient outcomes (e.g., risk of malignant
transformation) and that until such a system is
produced, deﬁnitive treatment of all oral epithelial
dysplasia is recommended.
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both of these systems, diagnosis is based on assessment
for the presence of various architectural and cytologic
deviations identiﬁed on light microscopy.
Histopathology is recognized as the gold standard in
the diagnosis of many mucosal diseases and indeed for
many other tissue and disease types.11 In the case of
OED, histopathology is also used as a clinical tool to
predict the risk of malignant transformation and often
guides clinical management and treatment of patients
and their mucosal lesions, with clinicians often moni-
toring milder cases of OED and actively treating through
surgical excision those deemed to be severe.12,13
However, the use of histopathology for the diagnosis and
categorization of OED has long been considered
imprecise, with poor inter- and intraobserver agreement
and low levels of reproducibility.14-16
The usefulness of OED grading has been contested in
the literature, and there is currently no consensus
regarding risk of malignant transformation based on
histopathology.12 Furthermore, most if not all studies
examining malignant transformation of OED have been
based on reinterpretation of specimens reexamined by
pathologists at the time of study and not on the original
interpretation of histologic ﬁndings by pathologists at
the time of diagnosis. The primary aim of this study was
to assess the rate of malignant transformation and
progression of OED based on pathologists’ histopatho-
logic interpretation at the time of diagnosis without any
further reinterpretation, in an effort to model a real-world
setting. The secondary aim was to identify whether there
were any demographic or specimen factors associated
with an increased risk of progression either to a higher
grade of OED or to OSCC, given these conditions of
interpretation.
MATERIALS AND METHODS
A retrospective audit of computerized biopsy reports
was conducted at Queensland Medical Laboratories,
a major Australian pathology laboratory service based in
Queensland, Australia. The organization comprises 22
laboratories that serve the state of Queensland and
Northern New South Wales. The central database
included reported biopsies of all anatomic locations
diagnosed from January 1, 1995. All reports were coded
and classiﬁed using the Systematised Nomenclature of
Medicine, Clinical Terms.
The central database was searched for biopsy reports
dated up to May 31, 2012, for all oral sites and diag-
noses of mucosal malignancy or dysplasia. Information
was collected on gender, age at diagnosis, residence,
biopsy location, and histopathologic diagnosis.
Anatomic locations were categorized as buccal
mucosa, gingiva, palate, tongue, ﬂoor of mouth, and
oral mucosa not otherwise speciﬁed. The external lipwas excluded in this study, because the majority of
cancers occurring in this anatomic location are associ-
ated with high levels of ultraviolet light exposure in the
Australian climate, an etiologic factor that does not
contribute to progression or malignant transformation
of the remaining oral mucosa.17 Residence was based
on postal code at the time of diagnosis and was broadly
categorized into urban and rural. The urban region was
further divided into metropolitan Brisbane and regional
areas.
Histopathology was based on the ﬁnal diagnosis re-
ported by the pathologist at the time of analysis. No
attempt at reexamining or reinterpreting the specimen
was undertaken. Histopathologywas categorized using 2
systems based on the ﬁnal diagnosis and pathologist
notes. The ﬁrst system was based on the currently
accepted 3-tier 2005 World Health Organization
Classiﬁcation, which separates dysplasia into mild,
moderate, and severe dysplasia/carcinoma in situ.1 A
second classiﬁcation, based on a binary system proposed
by Kujan et al.,10 was also applied to cases of OED.With
this system, OED was classiﬁed as being at either low
risk or high risk of malignant transformation.
For this study, malignant transformation was a diag-
nosis of OSCC made at least 6 months subsequent to
a diagnosis of OED. Progression was the diagnosis of
a higher grade of OED, based on a mild/moderate/
severe hierarchy, at least 6 months after the initial lower
grade diagnosis. These deﬁnitions did not discriminate
between oral subsites, as it was not possible to ascertain
with absolute certainty whether malignancy or subse-
quent OED developed within the exact site of previous
biopsy, and this fact underscores OED as a ﬁeld can-
cerization effect. Six months is the conventional cutoff
to account for biopsy sampling bias and coexisting
malignancy.14,18 Where multiple biopsies were under-
taken for a single patient within 6 months, the biopsy
reporting the highest level of dysplasia was used for
analysis. Patients with a history of head and neck
cancer were excluded.
To ensure all cases of OSCC were captured, data
were also obtained from the Queensland Oncology
Repository, which receives compulsory notiﬁcations of
cancers diagnosed throughout Queensland in the period
1982 to 2008. Cancers that were recorded with an ICD-
10 code of C01 to C14 were obtained and crossmatched
with cases of dysplasia to ascertain whether a history of
head and neck cancer existed and whether a cancer was
diagnosed outside the pathology laboratory used in this
study. Codes C02 to C06 were considered oral cancers
for this study.
Statistical analysis was undertaken using the R soft-
ware, version 2.15.0, and IBM SPSS software, version
20.0. For each case of OED, person-years at risk were
calculated as the time from diagnosis of OED to OSCC
Table I. Characteristics of patients who were biopsied




















Buccal mucosa 68 (17.8)
Floor of mouth 44 (11.5)
Palate 29 (7.6)
Gingiva 24 (6.3)












NOS, not otherwise speciﬁed; CIS, carcinoma in situ.
*Progression to a higher form of oral epithelial dysplasia; malignant
transformation not included.
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Annual malignant transformation was calculated based
on methods previously outlined, being the percentage
of OEDs that underwent malignant transformation over
the mean person-years at risk of the entire sample.18
Hazard ratios were calculated for risk of malignant
transformation compared with a reference group.
Univariate analysis (Fisher’s exact test) and 95% conﬁ-
dence intervals were employed to determine signiﬁcance,
which was set at a value of P < .05.
The study was conducted according to Human Ethics
Guidelines approved by the University of Queensland
(2007001478) and the Royal Brisbane and Women’s
Hospital (HREC/10/QRBW/336).
RESULTS
A total of 368 patients were included in the study, with
a mean age of diagnosis of 59.5 years (standard devi-
ation, 12.8 years). Amongst these patients, 383 OED
biopsies were identiﬁed (Tables I and II). Biopsies were
reported by 40 different pathologists; however, the
majority (n ¼ 225, 58.7%) were reported by 3 pathol-
ogists, all with advanced training in oral and maxillo-
facial pathology. Over 57% of the study population
were males, and almost 90% were aged over 45 years.
The tongue, followed by the buccal mucosa, was the
most common area for dysplasia, with two-thirds of
biopsies taken at these sites. Almost 60% of cases were
considered low-grade dysplasia.
A total of 1717 cases of oral cancer (excluding lip
and oropharynx) were registered among 1692 patients
in the Queensland Oncology Repository for the time
period 1995 to 2008. In comparison, 876 cases among
746 patients were identiﬁed among the records of the
pathology center. Crossmatching between the 2 data
sources revealed that 485 cancers (55.4%) that were
diagnosed at the pathology center were not registered
with the Oncology Repository.
Ten patients harboring 11 lesions representing 2.9%
of OEDs progressed to a higher level of tissue dysplasia
in a mean time of 1.3 years; 2 of these lesions
also subsequently developed malignancy (Table III).Malignant transformation was identiﬁed in 18 patients
(4.7%) in a mean time of 3.3 years (Table IV).
Progression to a higher grade of dysplasia and malig-
nant transformation both occurred most commonly
among females and in patients aged over 45 years.
Annual malignant transformation rates are reported
in Table V. For all oral sites and dysplasia grades, the
annual malignant transformation rate was approxi-
mately 1%. Transformation rates were highest for the
tongue, with 1.4% progressing to malignancy annually.
Unadjusted hazard ratios were calculated to deter-
mine if any patient, clinical, or histopathologic features
were associated with progression or malignant trans-
formation (Tables VI and VII). No signiﬁcant associa-
tions were found between any patient or clinical factors
with progression or transformation. Further exclusion
of OED cases that were not reported by pathologists
with advanced training in oral and maxillofacial
pathology did not show signiﬁcant associations
between progression and any patient or clinical factors.DISCUSSION
Histopathology has long been used not only as a diag-
nostic tool but also for its predictive value for precursor
epithelial diseases.19 This study aimed to describe the
predictive value of 2 conventional grading systems for
OED by investigating long-term outcomes of dysplastic
oral mucosal tissue in a real-world setting. The mean
Table III. Characteristics of patients and biopsies that developed a higher grade of dysplasia
No. Gender Locality
Initial dysplasia Progressive dysplasia
Interval (mo)*
Malignant
transformationAge (y) Year Grade Site Grade Site
1 M Regional 66 1999 Moderate Floor of mouth, NOS Severe/CIS Tongue, right ventral 15 No
2 F Regional 58 2001 Moderate Retromolar, NOS Severe/CIS Tongue, NOS 25 No
3 F Metro 71 2002 Moderate Buccal, right Severe/CIS Buccal, right 7 No
4 M Metro 44 2003 Mild Buccal, left Moderate Oral mucosa, NOS 43 No
5 M Rural 72 2005 Mild Tongue, right lateral Moderate Tongue, anterior 24 Yes
6 M Regional 56 2006 Mild Tongue, right Severe/CIS Tongue, right lateral 10 No
7 M Rural 62 2009 Moderate Tongue, right Severe/CIS Tongue, right lateral 11 Yes
8 F Rural 63 2009 Moderate Tongue, left Severe/CIS Tongue, left lateral 12 No
9y F Regional 74 2010 Moderate Buccal, right Severe/CIS Buccal, right 6 No
9y F Regional 74 2010 Moderate Hard palate, NOS Severe/CIS Palate, right 7 No
10 F Metro 81 2011 Mild Tongue, NOS Moderate Tongue, NOS 7 No
CIS, carcinoma in situ; NOS, not otherwise speciﬁed; M, male; F, female.
*Months between ﬁrst dysplasia and second dysplasia diagnosis.
yIn this instance there were 2 biopsies of 2 distinct sites within 1 patient.
Table IV. Characteristics of patients and biopsies that developed malignancy following dysplasia diagnosis
No. Gender Residence
Initial dysplasia
Malignancy site Interval (mo)*Age (y) Year Grade Site
1 F Regional 70 1998 Dysplasia NOS Tongue, lateral Tongue, NOS 63
2 F Regional 51 1999 Mild Tongue. Lateral Tongue, left 76
3 F Metro 65 1999 Moderate Tongue, right Tongue, left 43
4 M Regional 67 2001 Severe/CIS Buccal, left Buccal, NOS 69
5 M Regional 59 2001 Mild Tongue, NOS Tongue, NOS 59
6 M Rural 50 2001 Mild Gingiva, NOS Gingiva, lower 89
7 F Metro 87 2002 Mild Tongue, right lateral Buccal, NOS 69
8 F Regional 51 2003 Moderate Tongue, right lateral Tongue, NOS 6
9 F Regional 49 2004 Moderate Oral mucosa, NOS Gingiva, NOS 24
10 M Metro 41 2005 Mild Buccal, left Buccal, NOS 7
11 M Rural 72 2005 Mild Tongue, right lateral Tongue, right lateral 64
12 F Regional 42 2005 Moderate Tongue, left lateral Tongue, left 21
13 F Regional 63 2006 Dysplasia NOS Tongue, ventral Tongue, NOS 9
14 F Rural 66 2006 Moderate Tongue, left Tongue, right lateral 37
15 M Rural 53 2008 Mild Tongue, left Tongue, left 11
16 F Regional 70 2009 Mild Retromolar, right Buccal, right 31
17 F Metro 47 2009 Mild Tongue, left ventral Tongue, left 11
18 M Rural 62 2009 Moderate Tongue, right Tongue, left 28
CIS, carcinoma in situ; NOS, not otherwise speciﬁed; M, male; F, female.
*Months between ﬁrst dysplasia and second dysplasia diagnosis.
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consistent with previous studies of Western pop-
ulations.14,20,21 Approximately half of all dysplasias
occurred on the tongue, which also presented with the
highest rate of malignant transformation. This is
consistent with previous studies, which show the lateral
tongue and ﬂoor of mouth having the highest
rates of OED development and malignant trans-
formation.18,22,23 The buccal mucosa was distantly the
second most common area of OED development in this
study (n ¼ 68, 17.8%). Previous studies have reported
high rates of oral mucosal lesions at this site, which is
likely to be associated with placement of local tobacco
and betel products; however, there is no particular
propensity for OED development.18,24-26 An almost
20% rate of OED occurring in the buccal mucosa is inkeeping with rates reported by previous studies,26,27 but
there is signiﬁcant variation.21 Some authors have re-
ported the soft palate as a high-risk site,28 but due to the
limited data available in pathology reports, discrimi-
nation between OED of the hard and soft palate was not
possible in the present study. Less than 5% of OED
cases underwent malignant transformation at an annual
rate of approximately 1%, and approximately 3% pro-
gressed to a higher grade of dysplasia. No association
was noted between dysplasia grading and malignant
transformation. Furthermore, in this population, no
association was noted between any other clinical or
patient factors and malignant transformation.
The efﬁcacy of histopathologic grading of precursor
lesions as an indicator of malignant transformation has
long been contested in the literature.12,18,29 Current
Table V. Site- and grade-speciﬁc annual malignant transformation rates
n* Total Person-year follow-up
Annual malignant
transformation rate (%) Mean interval (y)y
Total 18 1941.42 0.93 3.32
Site
Tongue 13 187 922.50 1.41 3.19
Buccal mucosa 3 68 352.58 0.85 2.97
Gingiva 1 24 135.92 0.74 7.42
Oral mucosal NOS 1 31 156.67 0.64 2.00
Dysplasia grade
Mild dysplasia/low risk 9 221 1052.25 0.86 3.86
Moderate dysplasia 6 85 472.17 1.27 2.21
Severe dysplasia/CIS 1 55 282.42 0.35 5.75
High risk 7 140 754.58 0.93 2.71
NOS 2 22 134.58 1.49 3.00
CIS, carcinoma in situ; NOS, not otherwise speciﬁed.
*Number of cases that underwent malignant transformation.
yMean number of years between dysplasia diagnosis and malignancy.
Table VI. Association of clinicopathologic factors with malignant transformation
Malignant progression, n (%) No progression, n (%)
Unadjusted hazard ratio
(95% CI)*
Total 18 (4.7) 365 (95.3)
Gender
Female 11 (6.8) 155 (93.4) ref
Male 7 (3.2) 210 (96.8) 0.4868 (0.1929, 1.2287)
P ¼ .146
Age at diagnosis
45 years 2 (4.8) 40 (95.2) ref
>46 years 16 (4.7) 325 (95.3) 0.9853 (0.2347, 4.1364)
P ¼ 1.000
Residence
Remote 5 (6.4) 73 (95.3) ref
Urban 13 (4.3) 292 (95.7) 0.6649 (0.2444, 1.8092)
Metro 4 (3.7) 105 (96.3) 0.5725 (0.1588, 2.0636)
Regional 9 (4.6) 187 (95.4) 0.7163 (0.2479, 2.0702)
P ¼ .694
Site of dysplasia
Tongue 13 (7.0) 174 (93.0) ref
Buccal mucosa 3 (4.4) 65 (95.6) 0.6346 (0.1866, 2.1589)
Floor of mouth 0 44 (100.0) d
Palate 0 29 (100.0) d
Gingiva 1 (4.2) 23 (95.8) 0.5994 (0.0820, 4.3805)
Oral mucosa NOS 1 (3.2) 30 (96.8) 0.4640 (0.0629, 3.4222)
P ¼ .384
Dysplasia grade
Mild 9 (4.1) 212 (95.9) ref
Moderate 6 (7.1) 79 (92.9) 1.7333 (0.6362, 4.7223)
Severe/CIS 1 (1.8) 54 (98.2) 0.4465 (0.0578, 3.4500)
NOS 2 (9.1) 20 (90.9) 2.2323 (0.5142, 9.6913)
P ¼ .298
CIS, carcinoma in situ; ref, reference group; NOS, not otherwise speciﬁed.
*P value of Fisher exact test.
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a multistep, progressive, cumulative process of genetic
mutations that culminate in tumor formation and ulti-
mately invasion and metastasis.29,30 Although OSCC is
not linear in its development, there is general agreement
that it begins as a simple epithelial hyperplasia andprogresses through OED, with more severe dysplastic
changes signifying more extensive genetic aberra-
tions.30 The timeframe for this process is not known,
but is thought to be a relatively slow process, with
malignant transformation occurring within 10 years.18
Although this model may suggest that OSCC is an
Table VII. Association of clinicopathologic factors with dysplasia progression
Dysplasia progression, n (%) No progression, n (%)
Unadjusted hazard ratio
(95% CI)*
Total 11 (2.9) 372 (97.1)
Gender
Female 6 (3.6) 160 (96.4) ref
Male 5 (2.3) 212 (97.7) 0.4455 (0.1389, 1.4284)
P ¼ .542
Age at diagnosis
45 years 1 (2.4) 41 (97.6) ref
>46 years 10 (2.9) 331 (97.1) 1.2317 (0.1617, 9.3826)
P ¼ 1.000
Residence
Remote 3 (3.8) 75 (96.2) ref
Urban 8 (2.6) 297 (97.4) 0.6820 (0.1852, 2.5108)
Metro 3 (2.8) 106 (97.2) 0.7156 (0.1483, 3.4523)
Regional 5 (2.6) 191 (97.4) 0.6633 (0.1624, 2.7088)
P ¼ .851
Site of dysplasia
Tongue 5 (2.7) 182 (97.3) ref
Buccal mucosa 4 (5.9) 64 (94.1) 2.2000 (0.6085, 7.9535)
Floor of mouth 1 (2.3) 43 (97.7) 0.8500 (0.1018, 7.0940)
Palate 1 (3.4) 28 (96.6) 1.2897 (0.1562, 10.6491)
Gingiva 0 24 (100.0) d
Oral mucosa NOS 0 31 (100.0) d
P ¼ .663
Dysplasia grade
Mild 4 (1.8) 217 (98.2) ref
Moderate 7 (8.2) 78 (91.8) 4.5500 (1.3667, 15.1479)
Severe/CIS 0 55 (100.0) d
NOS 0 22 (100.0) d
P ¼ .298
CIS, carcinoma in situ; ref, reference group; NOS, not otherwise speciﬁed.
*P value of Fisher exact test.
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in the absence of deﬁnitive surgical intervention.
Conversely, malignant transformation may occur
despite active treatment and follow-up of mucosal
lesions exhibiting OED.12,29,31
The grading of OED attempts to convey to a clinician
the level of risk of malignancy, based on the progression
of carcinogenic tissue change. Grading of histopathology
should therefore be based on the natural biologic behavior
and validated against a relevant independent outcome,
which in this case is malignant transformation.11
Currently, there is inconsistency in the literature
regarding the usefulness of OED grading in predicting
malignant transformation.32 In a comparable population,
Warnakulasuriya et al.18 report annual transformation
rates of 1.8% and 5.6% for moderate and severe
dysplasia, respectively. The authors concluded that
severity of OED was signiﬁcantly associated with an
increased risk of malignant transformation. These ﬁnd-
ings are supported by those of Schepman et al.,33 Sil-
verman et al.,34 and Liu et al.,35 who report higher rates of
transformation among moderate, severe, and high-grade
dysplasia. However, there are an equal number of studies
reporting no association between transformation rates anddysplasia severity.14,21,22,25 Moreover, the presence of
OED has been reported by some authors as an insigniﬁ-
cant factor in predicting malignant transformation, with
high rates of progression in tissue exhibiting a history of
epithelial hyperplasia only.24,25,31,36 But this may simply
reﬂect the unpredictable timeframe of carcinogenesis as
well as treatment and follow-up patterns.
Generally, mild cases are monitored, and more severe
cases are excised.12,13 This routine management strategy
attempts to reduce the transformation risk of severe
OED by removing the transformed ﬁeld of epithelial
tissue. Selectively managing more severe cases aggres-
sively makes the natural progression of OED more
difﬁcult to assess, and the biases introduced by treat-
ment are difﬁcult to account for. In a recent systematic
review, Mehanna et al.37 reported that excision of OED
reduced the risk of malignant transformation but did not
eliminate the risk completely. Conversely, a 2006
Cochrane review reports that there is no evidence to
support surgical excision as an effective treatment for
the prevention of malignant transformation, but this
study focused on oral leukoplakia only.38
Holmstrup et al.31 report a higher rate of malignant
transformation among surgically treated oral potentially






Histologic diagnosis n Years Mean/median
Banoczy (1976), Banoczy
(1977)
Hungary OED 68 9 (13) 1-30 9.8
No dysplasia 602 31 (5)
Silverman (1984) United States OED 22 8 (36) d 7.2
No dysplasia 235 37 (16)
Lumerman (1995) United States OED 44 7 (16) >1-9 1.5
Schepman (1998) Netherlands Mod OED/Sev OED 47 11 (23) >1-17 2.5
No dysplasia/Mild OED 62 3 (5)
Cowan (2001) Northern Ireland OED 165 24 (15) 20 d
No dysplasia 1182 17 (1)
Hsue (2007) Taiwan OED 166 8 (5) 10 d
No dysplasia 1297 36 (3)
Arduino (2009) Italy OED 207 15 (7) 16 d
Ho (2009) Taiwan OED 33 8 (24) 3
No dysplasia 115 15 (13)
Warnakulasuriya (2011) Southeast England Mild OED 104 5 (5) 10 d
Mod OED 70 11 (16)
Sev OED 30 8 (27)
No dysplasia 1153 11 (1)
Brouns (2013) Netherlands No OED 88 8 (9) 15 1
Mild/Mod OED 40 6 (15)
Sev OED 16 2 (13)
OED, oral epithelial dysplasia; Mod, moderate; Sev, severe.
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treated), suggesting that complete excision does not
eliminate the risk of subsequent OSCC development.
Given the nonrandomized nature of the study by
Holmstrup et al., which only undertook complete ex-
cision of dysplastic oral mucosal lesions and those
presenting in high-risk sites, these ﬁndings should be
interpreted with caution. Statements such as those made
by Balasundaram et al.,39 describing a growing body of
evidence to support a view that excision of OED may
induce malignant transformation, are incorrect and
misleading. Balasundaram et al.39 reference both the
Holmstrup study31 and a single outdated animal study40
as veriﬁcation of their view, and they fall short in
reporting the limited generalizability of these studies
and indeed fail to highlight other studies supportive of
this notion. Although excision does not entirely elimi-
nate risk of transformation, it does reduce the risk
by removing the visible manifestation of dysplastic
mucosal ﬁelds.37
Holmstrup argues that there is a desperate need for
randomized clinical trials to ascertain whether surgical
treatment is effective in justiﬁably reducing risk of
malignant transformation of OED and further argues
that the blind surgical management of patients is more
unethical than conducting these large-scale randomized
clinical trials.41 We posit that short of stripping the
entire mucosal surface of the oral cavity and removing
the entire dysplastic ﬁeld, there is currently no way
to deﬁnitively ensure that risk of transformation issigniﬁcantly reduced or eliminated. This concept is
supported by Mehanna et al.37 in their meta-analysis,
which states that removing dysplasia reduces but does
not eliminate risk of OSCC formation. From both
a clinician and patient perspective, removal of overt,
clinically evident dysplasia seems both reasonable and
feasible. To date, clinical recognition of OED has
been challenging, and ongoing surveillance of these
lesions may be regarded as an ineffective treatment
option.21,24,27,41 Of particular concern are homogeneous
leukoplakias, which are especially problematic in their
management. Leukoplakia patches are idiopathic lesions
that may only be diagnosed in the absence of causative
factors and carry an increased risk of OSCC develop-
ment compared with normal mucosa.1 This current
deﬁnition excludes such white lesions as traumatic or
smokers’ keratosis, which do not carry an excessive risk
of OSCC. Historically, however, these conditions were
classiﬁed as leukoplakia in large-scale epidemiologic
studies, despite their benign nature, resulting in an
artiﬁcially low rate of OED and OSCC. This has
resulted in a general, perhaps inaccurate, consensus that
homogeneous leukoplakia lesions, by current deﬁni-
tions, have low rates of OED and transformation.6
Furthermore, the deﬁnition of leukoplakia implies
a heightened risk of OSCC. This contradicts entirely the
choice of surveillance as a ﬁrst-line management option
for true leukoplakia. In a recent study, we report an
almost 50% rate of OED among homogeneous leuko-
plakia and present a standardized system for the
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ﬁrst presentation.46 This may also be adapted and
applied to surveillance of potentially dysplastic lesions.
With regard to malignant transformation, the pro-
portion of cases that underwent transformation in the
present study is considerably low, with previous studies
reporting between 5% and 36% of all cases developing
malignancy (Table VIII).14,18,20,21,23-26,34,36,42 In an
effort to eliminate bias introduced by the pathologist’s
interpretation of OED grading, previous studies stan-
dardized the diagnostic criteria for OED and reanalyzed
each specimen. A recent meta-analysis reported an
annual malignant transformation rate of OED of
12.1%.37 Of a possible 28 relevant studies, half were
excluded due to lack of histopathologic diagnosis, lack
of segregation of dysplastic and nondysplastic mucosal
lesions, and short follow-up. In the present study no
attempt was made to standardize or reclassify OED
diagnoses or grading, as these ﬁndings are arguably
more reﬂective of actual clinical outcomes. Bosman43
makes a distinction between research histopathology
and applied histopathology, indicating that both are
essential for diagnosing and managing patients with
dysplastic changes. A study by Tilakaratne et al.19 in
2011 assessed the level of agreement between pathol-
ogists in determining the presence of various histo-
pathologic features of OED that are commonly used
throughout several classiﬁcation systems. Intraobserver
variability remained high among individual patholo-
gists for the majority of dysplastic features; how-
ever, interobserver consistency was poor between
pathologists.
In the current study, specialist training in oral and
maxillofacial pathology did not signiﬁcantly affect
transformation rates. Qualitative scrutiny of biopsy
reports also revealed that diagnostic terms varied
signiﬁcantly outside of conventional terminology
(mild/moderate/severe and low/high risk), suggestive
of the complexity of categorizing a continuous scale of
changes into a discrete, arbitrarily discriminated diag-
nosis. This has led to several revisions of OED classi-
ﬁcation, with the most recent being less than a decade
old.1 A consequence of this has been difﬁculty in
comparing studies across time, which produces chal-
lenges in interpreting current evidence. Furthermore,
with each new diagnostic classiﬁcation revision, the
burden on pathologists (who have a responsibility to
adopt these changes and to ensure that they remain
current) increases. Evidence would suggest, however,
that those in the health services ﬁeld are slow to adopt
innovation, which affects the diagnostic value of these
ever-changing classiﬁcations.44
Histopathology is a useful tool employed by clini-
cians to guide treatment of mucosal disease by pre-
dicting the risk of adverse outcomes. In the case ofOED, the current study did not ﬁnd a signiﬁcant asso-
ciation between the severity of OED and malignant
transformation, a ﬁnding suggestive of the complex
nature and biologic behavior of this condition and
associated oral potentially malignant disorders. It is
plausible that more severe cases are treated more
aggressively by wider excision and therefore the like-
lihood of transformation is reduced. Furthermore, given
the arbitrary and subjective nature of OED grading, the
initial diagnosis may have been inaccurate.
Reexamination of tissue specimens with calibrated
pathologists and taking a research rather than applied
histopathology approach may increase the signiﬁcance
of OED grading, but this does not seem to represent
a meaningful strategy that can be applied by clinicians
for patients in most real-world situations. Furthermore,
many OSCCs diagnosed within the pathology labora-
tory were not identiﬁed in the Oncology Repository,
suggesting that there may be cases of transformation
that may have been diagnosed within other laborato-
ries and not identiﬁed in this study. The Oncology
Repository requires compulsory notiﬁcation of all
malignancies, excluding external skin, with penalties
imposed for non-notiﬁcation.45 It is anticipated that
the rate of transformation would increase slightly if
other pathology laboratories were assessed for cases of
OSCC.CONCLUSION
Given the consistent lack of a meaningful correlation of
OED severity with patient outcomes in this study and
many others, it appears only prudent to undertake more
deﬁnitive treatment of oral potentially malignant lesions
exhibiting any grade of dysplasia (rather than to limit
this approach to severe cases) and accordingly to dis-
continue the “wait and watch” approach currently used
for milder cases. This is a function of the poor predic-
tive value of OED grading, which until reﬁned and
deemed a useful clinical tool to help predict trans-
formation cannot be used reliably as a guide for treat-
ment decision making. Although complete excision of
OED may be considered by some as overtreatment,
monitoring of retained overt dysplasia over time is
placing patients at risk of harm, given the uncertainty
and difﬁculty of gauging changes in the clinical
appearance of such lesions.REFERENCES
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